Restylane Shaype Versus Juvederm Volux for Chin Augmentation

Inclusion criteria

• At the time of consent, male and female subjects 18 years of age and older.
• Patients with established chin retrusion at Baseline (a score of mild, moderate, and severe severity on the Galderma Chin Retrusion Scale).
• Accepted the obligation not to receive any other facial procedures throughout the study duration.
• Understood and accepted the obligation and would be logistically able to appear for all scheduled follow-up visits.
• No previous lower face fillers for 12 months prior to this study.
• Capable of providing informed consent.

Exclusion criteria

• Patients without chin retrusion at Baseline, per the Galderma Chin Retrusion Scale.
• Current Pregnancy or lactation [sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)].
• Hypersensitivity to Restylane or Juvéderm products, hyaluronic acid filler or amide local anesthetics.
• Patients presenting with porphyria or any other liver diseases.
• Inability to comply with follow-up and abstain from facial injections during the study period.
• Heavy smokers, classified as smoking more than 12 cigarettes per day.
• History of severe or multiple allergies manifested by anaphylaxis since drug allergies might preclude optimal management of complications.
• Previous tissue revitalization therapy in the treatment area (i.e., the lower face) within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion.
• Previous facial surgery, including liposuction.
• Lifetime history of permanent implants in the treatment region (i.e., the lower face)
• Lifetime history of semi-permanent dermal fillers in the treatment region (i.e., the lower face).
• History or presence of any disease or lesion near or at the treatment area, including inflammation, active or chronic infection, including in the mouth, dentals, head, and neck region.
• Active facial psoriasis, eczema, acne, rosacea, perioral dermatitis, herpes zoster or any other facial condition that may increase the risk of cutaneous penetration of infective agents.
• Scars, deformities, piercings, or tattoos in the treatment areas.
• Facial cancer or precancer (e.g., actinic keratosis).
• History of radiation therapy in the treatment area.
• History of bleeding disorders, or treatment with thrombolytics, anticoagulants, or inhibitors of platelet aggregation (e.g., Aspirin or other non-steroid anti-inflammatory drugs [NSAIDs]), within 2 weeks before treatment.
• Patients with immune disorders such as systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, and Hashimoto's thyroiditis, or subjects using immunosuppressants.
• Patients with a tendency to form hypertrophic or keloid scars, or any other healing disorders.
• Patients with a tendency to form post-inflammatory hyperpigmentation.
• Patients with known hypersensitivity to lidocaine or agents structurally related to amide type local anesthetics (e.g., certain anti-arrhythmics).
• Patients administered dental block or topical administration of lidocaine within 2 weeks of treatment.
• Patients with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.
• Current remote infections (e.g., urinary tract, sinuses, intestinal tract, oral cavity)
• Planned dental procedures during the 2-week period before and after filler treatments, including teeth cleaning, tooth extraction and gum grafts.
• Planned COVID-19 vaccinations during the 2-week period before and after filler treatments.
• Lifetime history of cystic acne, due to increased risk of cyst development following filler treatment.